NATCO PHARMA | NGL FINE CHM | NATCO PHARMA/ NGL FINE CHM |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 12.7 | 26.9 | 47.0% | View Chart |
P/BV | x | 4.2 | 4.2 | 99.1% | View Chart |
Dividend Yield | % | 0.7 | 0.1 | 712.9% |
NATCO PHARMA NGL FINE CHM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NATCO PHARMA Mar-24 |
NGL FINE CHM Mar-24 |
NATCO PHARMA/ NGL FINE CHM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,108 | 2,425 | 45.7% | |
Low | Rs | 550 | 1,211 | 45.5% | |
Sales per share (Unadj.) | Rs | 223.3 | 548.0 | 40.7% | |
Earnings per share (Unadj.) | Rs | 77.5 | 66.9 | 115.9% | |
Cash flow per share (Unadj.) | Rs | 87.9 | 85.7 | 102.6% | |
Dividends per share (Unadj.) | Rs | 9.50 | 1.75 | 542.9% | |
Avg Dividend yield | % | 1.1 | 0.1 | 1,190.3% | |
Book value per share (Unadj.) | Rs | 326.8 | 425.0 | 76.9% | |
Shares outstanding (eoy) | m | 179.11 | 6.18 | 2,898.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.7 | 3.3 | 112.0% | |
Avg P/E ratio | x | 10.7 | 27.2 | 39.3% | |
P/CF ratio (eoy) | x | 9.4 | 21.2 | 44.5% | |
Price / Book Value ratio | x | 2.5 | 4.3 | 59.3% | |
Dividend payout | % | 12.3 | 2.6 | 468.4% | |
Avg Mkt Cap | Rs m | 148,509 | 11,232 | 1,322.2% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 5,250 | 451 | 1,163.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 39,988 | 3,387 | 1,180.7% | |
Other income | Rs m | 1,281 | 141 | 906.7% | |
Total revenues | Rs m | 41,269 | 3,528 | 1,169.7% | |
Gross profit | Rs m | 17,514 | 537 | 3,259.0% | |
Depreciation | Rs m | 1,868 | 116 | 1,604.5% | |
Interest | Rs m | 192 | 18 | 1,060.8% | |
Profit before tax | Rs m | 16,735 | 544 | 3,075.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,852 | 131 | 2,177.1% | |
Profit after tax | Rs m | 13,883 | 413 | 3,360.1% | |
Gross profit margin | % | 43.8 | 15.9 | 276.0% | |
Effective tax rate | % | 17.0 | 24.1 | 70.8% | |
Net profit margin | % | 34.7 | 12.2 | 284.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 40,235 | 2,127 | 1,891.9% | |
Current liabilities | Rs m | 9,728 | 866 | 1,123.5% | |
Net working cap to sales | % | 76.3 | 37.2 | 204.9% | |
Current ratio | x | 4.1 | 2.5 | 168.4% | |
Inventory Days | Days | 62 | 70 | 87.9% | |
Debtors Days | Days | 109 | 966 | 11.2% | |
Net fixed assets | Rs m | 28,634 | 1,429 | 2,004.2% | |
Share capital | Rs m | 358 | 31 | 1,159.0% | |
"Free" reserves | Rs m | 58,173 | 2,595 | 2,241.4% | |
Net worth | Rs m | 58,531 | 2,626 | 2,228.6% | |
Long term debt | Rs m | 0 | 7 | 0.0% | |
Total assets | Rs m | 68,869 | 3,555 | 1,937.0% | |
Interest coverage | x | 88.2 | 31.1 | 283.8% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.6 | 1.0 | 61.0% | |
Return on assets | % | 20.4 | 12.1 | 168.5% | |
Return on equity | % | 23.7 | 15.7 | 150.8% | |
Return on capital | % | 28.9 | 21.3 | 135.5% | |
Exports to sales | % | 0 | 70.3 | 0.0% | |
Imports to sales | % | 9.5 | 13.6 | 70.0% | |
Exports (fob) | Rs m | NA | 2,381 | 0.0% | |
Imports (cif) | Rs m | 3,798 | 459 | 826.9% | |
Fx inflow | Rs m | 27,347 | 2,409 | 1,135.3% | |
Fx outflow | Rs m | 3,798 | 509 | 746.3% | |
Net fx | Rs m | 23,549 | 1,900 | 1,239.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 12,116 | 205 | 5,920.4% | |
From Investments | Rs m | -10,327 | -268 | 3,850.9% | |
From Financial Activity | Rs m | -2,469 | -11 | 22,840.0% | |
Net Cashflow | Rs m | -615 | -74 | 827.4% |
Indian Promoters | % | 49.6 | 72.7 | 68.2% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 24.3 | 0.0 | 121,300.0% | |
FIIs | % | 17.5 | 0.0 | 87,550.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 50.4 | 27.3 | 184.8% | |
Shareholders | 302,944 | 14,575 | 2,078.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare NATCO PHARMA With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Natco Pharma | NGL FINE CHM | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 0.61% | 0.70% | 0.11% |
1-Month | 0.26% | -14.26% | -3.22% |
1-Year | 76.43% | -7.06% | 42.65% |
3-Year CAGR | 19.45% | -12.53% | 19.86% |
5-Year CAGR | 19.87% | 33.88% | 25.90% |
* Compound Annual Growth Rate
Here are more details on the Natco Pharma share price and the NGL FINE CHM share price.
Moving on to shareholding structures...
The promoters of Natco Pharma hold a 49.6% stake in the company. In case of NGL FINE CHM the stake stands at 72.7%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Natco Pharma and the shareholding pattern of NGL FINE CHM.
Finally, a word on dividends...
In the most recent financial year, Natco Pharma paid a dividend of Rs 9.5 per share. This amounted to a Dividend Payout ratio of 12.3%.
NGL FINE CHM paid Rs 1.8, and its dividend payout ratio stood at 2.6%.
You may visit here to review the dividend history of Natco Pharma, and the dividend history of NGL FINE CHM.
For a sector overview, read our pharmaceuticals sector report.
On Thursday, Indian share markets traded lower throughout the trading session and ended on a weak note.